Therapeutic effects of benralizumab assessed in patients with severe eosinophilic asthma: Real-life evaluation correlated with allergic and non-allergic phenotype expression
| Autor: | Giovanna Elisiana Carpagnano, Nicola Scichilone, Luigi Macchia, Alida Benfante, Claudia Crimi, Simona Pellegrino, Santi Nolasco, Giuseppe Spadaro, Alessandro Vatrella, Giuseppe Valenti, Giulia Scioscia, Maria D'Amato, Maria Filomena Caiaffa, Corrado Pelaia, Cecilia Calabrese, Domenico Ciotta, Girolamo Pelaia, Nunzio Crimi |
|---|---|
| Přispěvatelé: | Pelaia, C., Crimi, C., Benfante, A., Caiaffa, M. F., Calabrese, C., Carpagnano, G. E., Ciotta Jnr, D., D'Amato, M., Macchia, L., Nolasco, S., Pelaia, G., Pellegrino, S., Scichilone, N., Scioscia, G., Spadaro, G., Valenti, G., Vatrella, A., Crimi, N., Pelaia, Corrado, Crimi, Claudia, Benfante, Alida, Filomena Caiaffa, Maria, Calabrese, Cecilia, Elisiana Carpagnano, Giovanna, Ciotta, Domenico, D'Amato, Maria, Macchia, Luigi, Nolasco, Santi, Pelaia, Girolamo, Pellegrino, Simona, Scichilone, Nicola, Scioscia, Giulia, Spadaro, Giuseppe, Valenti, Giuseppe, Vatrella, Alessandro, Crimi, Nunzio, Pelaia C., Crimi C., Benfante A., Caiaffa M.F., Calabrese C., Carpagnano G.E., Ciotta Jnr D., D'amato M., Macchia L., Nolasco S., Pelaia G., Pellegrino S., Scichilone N., Scioscia G., Spadaro G., Valenti G., Vatrella A., Crimi N. |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Pulmonary and Respiratory Medicine
lcsh:Immunologic diseases. Allergy medicine.medical_specialty Vital capacity allergic and non allergic phenotypes Asthma exacerbation Settore MED/10 - Malattie Dell'Apparato Respiratorio benralizumab FEV1/FVC ratio chemistry.chemical_compound Prednisone Internal medicine IL-5 receptor Journal of Asthma and Allergy Immunology and Allergy Medicine Clinical significance Asthma Original Research Allergic and non-allergic phenotype business.industry Severe eosinophilic asthma Therapeutic effect Benralizumab medicine.disease chemistry asthma exacerbations Exhaled nitric oxide allergic and non-allergic phenotypes business lcsh:RC581-607 Allergic and non-allergic phenotypes Asthma exacerbations Benralizumab IL-5 receptor Severe eosinophilic asthma Allergic and non-allergic phenotypes Asthma exacerbations medicine.drug |
| Zdroj: | Journal of Asthma and Allergy Journal of Asthma and Allergy, Vol Volume 14, Pp 163-173 (2021) |
| Popis: | Corrado Pelaia,1 Claudia Crimi,2 Alida Benfante,3 Maria Filomena Caiaffa,4 Cecilia Calabrese,5 Giovanna Elisiana Carpagnano,6 Domenico Ciotta Jnr,7 Maria D’Amato,8 Luigi Macchia,9 Santi Nolasco,2 Girolamo Pelaia,1 Simona Pellegrino,7 Nicola Scichilone,3 Giulia Scioscia,10 Giuseppe Spadaro,11 Giuseppe Valenti,12 Alessandro Vatrella,7 Nunzio Crimi2 1Department of Health Sciences, University “Magna Graecia” of Catanzaro, Catanzaro, Italy; 2Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy; 3Department of Biomedicine and Internal and Specialistic Medicine, University of Palermo, Palermo, Italy; 4Allergology and Clinical Immunology Unit, University of Foggia, Foggia, Italy; 5Department of Translational Medical Sciences, University of Campania “Luigi Vanvitelli”, Foggia, Italy; 6Department of Basic Medical Sciences, Neuroscience and Sense Organs, Section of Respiratory Disease, University “Aldo Moro” of Bari, Bari, Italy; 7Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy; 8Division of Pneumology, “V. Monaldi” University Hospital, Naples, Italy; 9Allergology and Clinical Immunology Unit, University “Aldo Moro” of Bari, Bari, Italy; 10Department of Medical and Surgical Sciences, Institute of Respiratory Diseases, University of Foggia, Foggia, Italy; 11Allergology and Immunology Unit, University “Federico II” of Naples, Naples, Italy; 12Allergology and Pulmonology Unit, Provincial Outpatient Center of Palermo, Palermo, ItalyCorrespondence: Corrado PelaiaDepartment of Health Sciences, University “Magna Graecia” of Catanzaro, Catanzaro, ItalyTel + 39 0961 3647007Email pelaia.corrado@gmail.comBackground: Benralizumab can be utilized as add-on biological treatment of severe eosinophilic asthma. However, so far only a few real-life studies have been published with regard to the use of this anti-IL-5 receptor humanized monoclonal antibody.Objective: The primary aim of this multicenter observational investigation has been to assess the therapeutic effects of benralizumab in patients with severe uncontrolled, corticosteroid refractory eosinophilic asthma. The secondary objective was to evaluate the efficacy of benralizumab with regard to positive or negative skin prick test (SPT).Methods: Clinical, functional, and laboratory parameters were evaluated in order to verify the therapeutic actions of benralizumab in atopic and non atopic subjects with difficult-to-treat eosinophilic asthma. Moreover, a comparative evaluation was carried out in relation to the presence or absence of SPT positivity.Results: After 6 months of add-on biological therapy with benralizumab, our 111 patients experienced a marked improvement of their severe eosinophilic asthma, expressed by significant changes in asthma exacerbation rate, prednisone intake, daily use of short-acting β2-adrenergic agonists (SABA), asthma control test (ACT) score, asthma quality of life questionnaire (AQLQ) score (56 patients), forced expiratory volume in one second (FEV1), forced vital capacity (FVC), blood eosinophil count, blood basophil count (59 patients), and fractional exhaled nitric oxide (FeNO) levels (39 patients). In addition, significantly more effective outcomes were detected in patients with positive SPT, when compared to subjects with negative SPT, only in regard to asthma exacerbation number, ACT score, and daily SABA utilization. No significant correlation was found between serum IgE concentrations and each of all measured parameters.Conclusion and Clinical Relevance: Taken together, the results of this real-world study indicate that in both allergic and non-allergic subjects benralizumab can be used as a valuable pharmacotherapeutic option for add-on biological therapy of severe eosinophilic asthma, regardless of SPT positivity or negativity.Keywords: severe eosinophilic asthma, allergic and non-allergic phenotypes, asthma exacerbations, IL-5 receptor, benralizumab |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|